<DOC>
	<DOCNO>NCT01657955</DOCNO>
	<brief_summary>The purpose study determine whether bendamustine effective treatment initial treatment Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>Bendamustine Hydrochloride Injection Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients must diagnosis CLL ; No prior standard treatment CLL ; Binet stage B , C symptomatic stage A ; Needs treatment control diseases ; ( Eastern Cooperative Oncology Group ) ECOG performance status ≤ 2 Life expectancy ≥3 month Written inform consent Patients diagnose treated malignant tumor CLL ( include active central nervous system lymphoma ) within one year prior enter study Transformation Richter 's syndrome , prolymphocytic leukemia ( PLL ) Autoimmune hemolytic anemia require glucocorticoid therapy Autoimmune thrombocytopenia require glucocorticoid therapy Alanine aminotransferase ( ALT ) ＞3 time upper limit normal value , Aspartate aminotransferase ( AST ) ＞3 time upper limit normal value , Total bilirubin ( TBIL ) ＞2 time upper limit normal value , serum creatinine＞1.5 time upper limit normal value ; Other serious Concomitant disease affect participation study ( uncontrolled diabetes , gastric ulcer , cardiac pulmonary disease , active phase autoimmune disease ; Serious uncontrolled infection ; Central nervous system dysfunction clinical symptom ; Patients receive major surgery within 30 day prior study entry ; Pregnant lactate woman Allergic study drug mannitol Participation clinical trial within 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>